Amicus Therapeutics

Q3 2025 +2.11%Q2 2025 -2.45%Q1 2025 -13.02%Q4 2024 -2.94%Q3 2024 -6.47%Q2 2024 +14.80%Q1 2024 -8.97%Q4 2023 -7.44%Q3 2023 -14.82%Q2 2023 +9.13%Q1 2023 -4.18%Q4 2022 -3.87%Q3 2022 +6.53%Q2 2022 +17.45%Q1 2022 +7.50%Q4 2021 0.00%Q3 2021 -3.77%Q2 2021 +8.47%Q1 2021 -1.54%Q4 2020 -9.04%Q3 2020 -1.30%Q2 2020 -5.32%Q1 2020 -1.60%Q4 2019 -4.24%Q3 2019 +3.24%Q2 2019 -8.54%Q1 2019 -4.75%Q4 2018 +11.99%Q3 2018 -5.99%Q2 2018 +4.67%Q1 2018 -4.73%Q4 2017 -6.21%Q3 2017 -10.42%Q2 2017 +1.06%Q1 2017 +1.18%Q4 2016 +14.48%Q3 2016 +28.42%Q2 2016 -9.51%Q1 2016 -9.56%Q4 2015 -4.35%Q3 2015 +8.94%Q2 2015 -16.09%Q1 2015 -1.49%Q4 2014 -0.47%Q3 2014 -0.52%Q2 2014 -2.82%Q1 2014 +0.47%Q4 2013 +2.78%Q3 2013 +3.94%Q2 2013 +7.75%Q1 2013 -1.27%Q4 2012 +10.97%Q3 2012 -13.28%Q2 2012 -5.54%Q1 2012 +6.36%Q4 2011 -4.93%Q3 2011 +3.91%Q2 2011 +6.70%Q1 2011 -1.09%Q4 2010 -4.41%Q3 2010 -2.53%Q2 2010 +9.96%Q1 2010 -1.31%

Nov 06, 2024

•

Sep 30, 2024

Amicus Therapeutics Q3 2024 Earnings Report

Amicus Therapeutics reported Q3 2024 results with total revenue of $141.5M, a 37% increase year-over-year and raised 2024 total revenue growth guidance to 30%-32% at CER.

Key Takeaways

Amicus Therapeutics announced strong Q3 2024 results, driven by excellent commercial performance of Galafold and Pombiliti + Opfolda, exceeding expectations and achieving non-GAAP profitability for the full year 2024.

Total revenue reached $141.5M, a 37% increase year-over-year.

Galafold revenue was $120.4M, up 20% year-over-year.

Pombiliti + Opfolda revenue reached $21.1M, up 33% from Q2 2024.

2024 total revenue growth guidance raised to 30%-32% at CER.

Previous year: -$0.07

-242.9%

Gross Profit

$128M

Previous year: $93.6M

Previous year: -$39.9M